Correspondence 0001683168-23-009078 from CNS Pharmaceuticals, Inc. (CNSP)

CNS Pharmaceuticals, Inc.
Date: Dec. 26, 2023 · CIK: 0001729427 · Accession: 0001683168-23-009078

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-275973

Date

December 26, 2023

Author

Christopher Downs

Form

CORRESP

Company

CNS Pharmaceuticals, Inc.

Letter

CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027

December 26, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Re: CNS Pharmaceuticals, Inc.

Registration Statement on Form S-1 (the “Registration Statement”)

File No. 333-275973

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on December 21, 2023 regarding the acceleration of the effectiveness of the above-referenced Registration Statement to 5:00 P.M. (Eastern Time) on December 26, 2023. We hereby formally withdraw our prior request for acceleration of the effective date of such Registration Statement.

Very truly yours,
CNS Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027

December 26, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

 Re: CNS Pharmaceuticals, Inc.

    Registration Statement
on Form S-1 (the “Registration Statement”)

    File No. 333-275973

Ladies and Gentlemen:

Reference is made to our letter,
filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on December 21, 2023 regarding the acceleration of
the effectiveness of the above-referenced Registration Statement to 5:00 P.M. (Eastern Time) on December 26, 2023. We hereby formally
withdraw our prior request for acceleration of the effective date of such Registration Statement.

  Very truly yours,

  CNS Pharmaceuticals, Inc.

  By: /s/ Christopher Downs

  Name: Christopher Downs

  Title: Chief Financial Officer

cc:	Cavas Pavri, ArentFox Schiff LLP

SecProbe.io